All market verdicts

ABBV DOWN market verdict | Ezbrisk

Published: 1785537649833

Anomaly score: 0.0

Confidence: 0.75

Market summary

ABBV beats on revenue, EPS; trims guidance on Apogee deal

Ezbrisk assessment

AbbVie delivered strong Q2 results with double-digit revenue growth and adjusted EPS beating expectations, but the stock slipped as management slightly lowered full-year guidance to account for dilution from the pending Apogee Therapeutics acquisition.

Sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260731.htm, https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

Verdict ID: e43abfc6-adc4-4a18-b4cf-8bc80f4b3b22